3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
17
Melanoma
16
Kidney Neoplasms
11
Neoplasm Metastasis
10
Uterine Cervical Neoplasms
9
Prostatic Neoplasms
9
Breast Neoplasms
7
Ovarian Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Anus Neoplasms
6
Vaginal Neoplasms
5
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Penile Neoplasms
5
Pancreatic Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Oropharyngeal Neoplasms
4
Lymphoma
4
Lung Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Merkel Cell
4
Vulvar Neoplasms
3
Neuroblastoma
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Esophageal Neoplasms
3
Wilms Tumor
2
Interventions
Nivolumab
14
Ipilimumab
11
Specimen Handling
10
CTLA-4 Antigen
7
pembrolizumab
6
cabozantinib
6
Sunitinib
6
Magnetic Resonance Spectroscopy
6
Axitinib
5
pazopanib
4
Biopsy
4
Radiosurgery
3
lenvatinib
2
fludarabine
2
Everolimus
2
Blood Specimen Collection
2
tivozanib
1
sodium-iodide symporter
1
sitravatinib
1
belzutifan
1
atezolizumab
1
aldesleukin
1
Zoledronic Acid
1
Tissue Banks
1
Selenomethionine
1
Radiotherapy
1
Radiopharmaceuticals
1
Pluvicto
1
Nephrectomy
1
Molecular Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Clear-cell metastatic renal cell carcinoma
×
fludarabine
×
Genitourinary
×
Clear all
NCT07551349
2026-04-24
DUAL-NK RCC
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled
NCT04696731
2025-09-25
TRAVERSE
Allogene Therapeutics
Phase 1
Active not recruiting
120 enrolled